Surgery is still the main treatment for esophageal cancer, however, the complication and mortality rate of open esophagectomy is high. As a result, the thoracoscopic- laparoscopic minimally invasive esophagectomy (MIE) was developed. The MIE mainly comprised two surgical approaches: MIE McKeown approach (cervical anastomosis) and MIE Ivor-Lewis approach (intrathoracicanastomosis). The MIE with intrathoracic anastomosis (Ivor-Lewis) is increasingly used for the treatment of mid and lower esophageal cancers. Our study is trying to compare the safety, feasibility, and short-term and long- term outcomes between MIE Ivor-Lewis approach and MIE McKeown approach for the treatment of lower thoracic esophageal cancer and esophageal- gastric junction.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
272
minimally invasive esophagectomy (MIE) with intrathoracic anastomosis
minimally invasive esophagectomy (MIE) with cervical anastomosis
Yunpeng Zhao
Jinan, Shandong, China
Overall postoperative complications
Overall postoperative complication rates
Time frame: within one month
Operating time
Operating time in minutes
Time frame: 1 day
Lymph nodes harvested
Lymph nodes harvested in number
Time frame: 1 day
Blood loss
Blood loss in milliliter
Time frame: 1 day
Anastomotic leak
Anastomotic leak in rate
Time frame: within one month
Pulmonary complication
Pulmonary complication in rate
Time frame: 1 month
Anastomotic stenosis
Anastomotic stenosis in rate
Time frame: within three months
recurrent laryngeal nerve injury
recurrent laryngeal nerve injury in rate
Time frame: within three months
Chylothorax
Chylothorax in rate
Time frame: within one month
Cardiac arrhythmia
Cardiac arrhythmia in rate
Time frame: within one month
Laboratory findings
Three-day postoperative laboratory findings including ALB, PA, Glob, etc.
Time frame: within 3 days
Hospital stay
Hospital stay in days
Time frame: within 60 days
mortality
mortality in rate
Time frame: within 30 and 90 days
progression-free survival
progression-free survival in rate
Time frame: within 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.